Randomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer
Volunteers
Health Professionals
What is the purpose of this trial?
This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating patients with high-risk prostate cancer undergoing surgery. Androgen can cause the growth of prostate cancer cells. Hormone therapy using androgen receptor antagonist ARN-509, abiraterone acetate, and gonadotropin-releasing hormone analog (GnRH agonist) may fight prostate cancer by lowering the levels of androgen the body makes. Prednisone may either kill the tumor cells or stop them from dividing. Giving androgen receptor agonist ARN-509 with or without abiraterone acetate, GnRH agonist and prednisone may work better in treating patients with prostate cancer.
- Trial withRutgers, The State University of New Jersey
- GenderMale only
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Alessia Donadio, MD
- Anca Bulgaru, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Daniel P. Petrylak, MD
- Harold Tara Jr, MD
- Jason Haldas, MD
- Joseph Brito III, MD
- Joseph Kim, MD
- Joseph Renzulli, MD, FACS
- Lynn Mastrianni
- Matthew Austin, MD
- Meaghan Conway
- Michael Hurwitz, MD, PhD
- Michael S. Leapman, MD, MHS
- Michelle Laspino
- Preston C. Sprenkle, MD
- Robert Legare, MD
- Stephen Lattanzi, MD
- Last Updated05/07/2024
- Study HIC#2000031291